JDRF

Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study

Retrieved on: 
Thursday, June 15, 2023

Through its Industry Discovery & Development Partnerships ("IDDP") program, JDRF will provide US$2 million in funding to support Zucara's planned Phase 2a study of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus ("ZONE").

Key Points: 
  • Through its Industry Discovery & Development Partnerships ("IDDP") program, JDRF will provide US$2 million in funding to support Zucara's planned Phase 2a study of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus ("ZONE").
  • Zucara expects to begin patient dosing in the third quarter of 2023.
  • "JDRF has been a long-time partner of Zucara, supporting the development of ZT-01 from early discovery studies to this planned Phase 2 study soon underway," said Richard Liggins PhD, Zucara Therapeutics' Chief Scientific Officer.
  • "JDRF is excited to support Zucara's development of a novel therapy with the potential to protect against nocturnal hypoglycemia and help people with T1D achieve better glucose control."

Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes

Retrieved on: 
Thursday, June 1, 2023

The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

Key Points: 
  • The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.
  • Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.
  • Details of the presentation are as follows:
    Additional meeting information can be found on the IDS website: https://www.idsparis2023.com/_files/ugd/d65629_717d6a377fae45dc95b0ebb26...

Celebrating 30 years of the Sun Life Walk to Cure Diabetes for JDRF

Retrieved on: 
Thursday, June 1, 2023

TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- The Sun Life Walk to Cure Diabetes for JDRF is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research.

Key Points: 
  • TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- The Sun Life Walk to Cure Diabetes for JDRF is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research.
  • Funds raised from the Sun Life Walk to Cure Diabetes for JDRF will help to accelerate the pace of the most promising type 1 diabetes research.”
    Abbott’s Diabetes Care division has returned as the Walk’s National Premiere Partner.
  • “The JDRF Walk is a long-standing fundraiser that helps bring people from across Canada together to raise funds for those living with type 1 diabetes.
  • It’s programs like these that help build healthier and more sustainable communities.”
    Learn more about the 2023 Sun Life Walk to Cure Diabetes for JDRF and help us move T1D research forward faster: jdrfwalk.ca

JDRF Encourages Everyone Living with Diabetes to be Proactive about Eye Health in Recognition of Healthy Vision Month

Retrieved on: 
Thursday, May 18, 2023

NEW YORK, May 18, 2023 /PRNewswire/ -- In recognition of Healthy Vision Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, encourages everyone living with diabetes to be proactive about their eye health. Eye diseases like diabetic retinopathy, a condition that can cause vision loss and blindness, occur over time in more than half of people with diabetes. Anyone living with diabetes, including people with T1D, type 2 diabetes, and gestational diabetes, can develop diabetic retinopathy. However, early detection of diabetes related eye disease and timely, appropriate treatment can reduce the risk of blindness by over 95%.

Key Points: 
  • NEW YORK, May 18, 2023 /PRNewswire/ -- In recognition of Healthy Vision Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, encourages everyone living with diabetes to be proactive about their eye health .
  • Eye diseases like diabetic retinopathy, a condition that can cause vision loss and blindness, occur over time in more than half of people with diabetes.
  • Anyone living with diabetes, including people with T1D, type 2 diabetes, and gestational diabetes, can develop diabetic retinopathy.
  • "Eye diseases like diabetic retinopathy are a lingering reality for people living with diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF.

Humacyte First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, May 12, 2023

DURHAM, N.C., May 12, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • ET today -
    DURHAM, N.C., May 12, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate accomplishments.
  • There was no revenue for the first quarter of 2023, compared to $0.2 million for the first quarter of 2022.
  • Research and development expenses were $17.3 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022.
  • Net cash used in operations was $18.6 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022.

Panbela Provides Business Update and Reports Q1 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023

MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2023.

Key Points: 
  • MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2023.
  • Poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), which took place April 14-19, 2023.
  • Announced the first patient enrolled in a Phase II double-blind, randomized study to evaluate CPP-1X-T (eflornithine tablets) for recent onset type 1 diabetes.
  • Research and development expenses were $3.5 million in the first quarter of 2023, compared to $2.2 million in the first quarter of 2022.

Sonoma Bio Co-Founder and Chief Executive Officer Jeffrey Bluestone, Ph.D., Elected to the National Academy of Sciences

Retrieved on: 
Thursday, May 4, 2023

Each year, scientists are elected to membership by their peers for their outstanding contributions to research.

Key Points: 
  • Each year, scientists are elected to membership by their peers for their outstanding contributions to research.
  • Members are tasked with providing science, engineering, and health policy advice to the federal government and other organizations.
  • “I am humbled by the honor of being elected to the National Academy of Sciences,” said Dr. Bluestone.
  • Dr. Bluestone was elected to the National Academy of Medicine in 2013.

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

Retrieved on: 
Thursday, April 27, 2023

Humacyte’s BVP is designed to deliver insulin-producing islets using Humacyte’s investigational tissue-engineered blood vessel, the Human Acellular Vessel™ (HAV™).

Key Points: 
  • Humacyte’s BVP is designed to deliver insulin-producing islets using Humacyte’s investigational tissue-engineered blood vessel, the Human Acellular Vessel™ (HAV™).
  • JDRF will provide Humacyte with funding to support the development and testing of the BVP.
  • “We are proud to be collaborating with JDRF, one of the leading organizations in the world focused on T1D research,” said Dr. Laura ​​Niklason, founder and CEO of Humacyte.
  • “Humacyte’s HAV technology, combined with insulin-producing islets, may constitute a groundbreaking development in the treatment of T1D in the future.

Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Monday, April 24, 2023

The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.

Key Points: 
  • The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.
  • The presentation included an introduction to Evotec’s proprietary GMP process for manufacturing iPSC-derived ILCs for use in Sernova’s Cell Pouch, as well as encouraging results from multiple studies using a standard mouse model of T1D.
  • ILCs implanted into Sernova’s Cell Pouch demonstrated rapid normalization of glycemic control in the streptozotocin (STZ)-induced diabetic NSG (NOD.SCID.IL-2Rgammanull) mouse model.
  • “These results demonstrate that Evotec’s ILCs in the Cell Pouch can become fully functional endocrine islets following implantation, with potency equivalent to human islets.

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 20, 2023

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
  • Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine.
  • I’m thrilled he’ll be joining us to advance this work.”
    Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.